The document discusses a label-free biosensing technology utilizing surface plasmon resonance (SPR) for detecting viruses, highlighting the expertise of researchers Ilya Ankudinov and Vitaliy Gorelov. It outlines the market potential for diagnostic medical devices, estimated at $1.5 billion, and indicates a distribution strategy targeting hospitals and labs. An initial investment of $2 million is planned for prototype creation and production setup, with future investments aimed at mass production and marketing.